What Does the Evidence Say About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Targeted Risk Assessment

If you've taken Ozempic and now experience persistent nausea, vomiting, or feeling full too quickly, you may be wondering if the medication is the cause. Decades of pharmacovigilance have established that all drugs carry potential risks, and the link between GLP-1 receptor agonists and delayed gastric emptying is now a recognized area of investigation. This page reviews the current evidence, including FDA warnings and clinical findings, to help you understand the facts.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Among its known adverse effects, gastrointestinal complications are prominent, and emerging evidence has raised concerns about a potential link between Ozempic use and gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological profile of Ozempic, mechanistic pathways that may connect the drug to this condition, and risk considerations relevant to affected patients, including settlement-related factors. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life. While gastroparesis has multiple etiologies, including diabetes (which is also the primary indication for Ozempic), drug-induced forms are recognized, and GLP-1 receptor agonists have been implicated due to their effects on gastric motility.

Clinical Trial Data and Adverse Reaction Profiles

Ozempic’s pharmacology includes a mechanism that slows gastric emptying, which is part of its therapeutic action to reduce postprandial glucose excursions. However, this effect can become pathological in some patients. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg and 36.4% with Ozempic 1 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also higher: 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, though gastroparesis specifically is not listed as a separate adverse reaction in these tables. Additional gastrointestinal adverse reactions reported with Ozempic at frequencies below 5% include dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these symptoms overlap with those of gastroparesis, the prescribing information does not explicitly warn about gastroparesis as a potential adverse effect. The warnings section of the label addresses hypersensitivity reactions, including anaphylaxis and angioedema, but does not mention gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This absence of a specific warning is a key risk anchor for patients who may develop gastroparesis while using Ozempic.

Mechanistic Link and Risk Considerations for Settlement

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting vagal nerve activity and relaxing the gastric fundus. In susceptible individuals, this effect may become persistent, leading to gastroparesis. The timeline between exposure and documented harm can vary; some patients report symptoms during dose escalation, while others develop them after prolonged use. The clinical trial data show that gastrointestinal adverse reactions are most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that the risk may be highest when the drug is initiated or the dose is increased. For patients who develop gastroparesis after using Ozempic, settlement-related considerations include the adequacy of warnings provided by the manufacturer. The current label does not list gastroparesis as a specific adverse reaction, which may be relevant in legal claims alleging failure to warn. Additionally, the timeline between exposure and harm is critical; patients must demonstrate that their gastroparesis occurred after starting Ozempic and that other causes, such as diabetic gastroparesis, were ruled out. The clinical trial data showing higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo provide a basis for establishing a causal link, though individual cases require careful medical evaluation. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, and its pharmacological effect of delaying gastric emptying raises a plausible mechanistic link to gastroparesis. The prescribing information does not explicitly warn about this condition, which may be a factor in settlement discussions. Patients affected by gastroparesis after using Ozempic should seek medical evaluation to confirm the diagnosis and document the timeline of exposure. Legal considerations may hinge on the adequacy of warnings and the strength of evidence linking the drug to the harm. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In some patients, this effect can become pathological, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trial data show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), though gastroparesis is not explicitly listed as a separate adverse reaction.

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy, and evidence that other causes (e.g., diabetic gastroparesis) have been ruled out. The timeline between starting Ozempic and symptom onset is critical. The absence of a specific warning about gastroparesis on the label may support claims of failure to warn.

Does the Ozempic label warn about gastroparesis?

No, the current prescribing information for Ozempic does not list gastroparesis as a specific adverse reaction. The warnings section addresses hypersensitivity reactions but not gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission is a key factor in legal claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.